Team:Slovenia

From 2012.igem.org

(Difference between revisions)
Line 158: Line 158:
thead.normal{ background: #0C5DA5; color:#ffffff; border: 1px #d8d8d8 solid; }
thead.normal{ background: #0C5DA5; color:#ffffff; border: 1px #d8d8d8 solid; }
tbody .normal{ background: #fff; }
tbody .normal{ background: #fff; }
 +
 +
table.outcome { border-collapse: collapse; margin: auto; width:90%; margin-bottom:15px; }
 +
td.outcome, th.normal { padding-left: 1.4em; padding-right: 1.4em; padding-top: 0.4em; padding-bottom: 0.4em; border: 1px #d8d8d8 solid; }
 +
thead.outcome{ background: #0C5DA5; color:#ffffff; border: 1px #d8d8d8 solid; }
 +
tbody .outcome{ background: #fff; }
 +
ul.circle {
 +
list-style-type:circle;
 +
}
Line 220: Line 228:
.abstract {background:#0C5DA5; color:#ffffff; padding:10px; border-radius:5px;}
.abstract {background:#0C5DA5; color:#ffffff; padding:10px; border-radius:5px;}
-
</style>
 
 +
table.splash {position:relative;}
 +
td.splash, th.splash {width:300px; height:300px;}
 +
thead.splash{ background: #0C5DA5; color:#ffffff; border: 0px #d8d8d8 solid; }
 +
tbody .splash{ background: #fff; }
 +
 +
td.splash .ttip{
 +
position:absolute;
 +
left:100px;
 +
visibility:hidden;
 +
z-index:100;
 +
width:700px;
 +
opacity:0.85;
 +
background:cyan;
 +
border-radius: 30px;
 +
font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;
 +
padding: 10px 10px 10px 10px;
 +
}
 +
 +
td.splash .pic{
 +
position:absolute;
 +
visibility:visible;
 +
z-index:1;
 +
}
 +
 +
td.splash .pic2{
 +
position:absolute;
 +
visibility:hidden;
 +
z-index:10;
 +
}
 +
 +
td.splash:hover > .ttip
 +
{
 +
visibility:visible;
 +
}
 +
 +
 +
td.splash:hover .pic
 +
{
 +
 +
}
 +
 +
</style>

Revision as of 15:36, 24 September 2012


Switch-IT :: Inducible Therapeutics

Currently, biological drug-based therapies require periodic invasive application. Often, due to their systemic administration, adverse effects are observed. Furthermore, large quantities of these substances are needed because of their distribution throughout the body. This, coupled with expensive production and especially purification, imposes a great burden on health systems. We aim to develop a safe and cost-effective biological delivery system for biopharmaceuticals, which would increase the quality of patients' lives, because it would minimize the number of required procedures. This type of delivery system would increase patient compliance to the therapy while the local administration will reduce the side-effects associated with current treatments. We plan to design the mammalian cells-based delivery system to be regulated by the digital logic from the outside.

Retrieved from "http://2012.igem.org/Team:Slovenia"